Nur Savas Irem, Ozturk Akin, Kavas Murat, Bulut Ismet, Alparslan Sumeyye, Aydogan Eroglu Selma, Atinkaya Baytemir Cansel, Kolay Murat, Coskun Abdurrahman
Acibadem Mehmet Ali Aydınlar University, School of Medicine, Department of Biochemistry, Istanbul, Turkey.
University of Health Sciences, Istanbul Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Medical Oncology, Istanbul, Turkey.
J Med Biochem. 2021 Jun 5;40(3):237-244. doi: 10.5937/jomb0-25629.
Insulin-like growth factor binding protein-4 (IGFBP-4), a member of the insulin-like growth factor (IGF) family, transports, and regulates the activity of IGFs. The pregnancy-associated plasma protein-A (PAPP-A) has proteolytic activity towards IGFBP-4, and both proteins have been associated with a variety of cancers, including lung cancer. Thus, we aimed to evaluate the use of IGFBP-4 and PAPP-A as potential biomarkers for lung cancer. Eighty-three volunteers, including 60 patients with lung cancer and 23 healthy individuals, were included in this study. The patients with lung cancer were selected based on their treatment status, histological subgroup, and stage of the disease. Enzyme-linked immunosorbent assays were used to assess the serum levels of IGFBP-4 and PAPPA, whereas the IGF-1 levels were measured using a chemiluminescent immunometric assay. The serum IGFBP-4 levels in all patient groups, regardless of the treatment status and histological differences, were significantly higher than those in the control group (p<0.005). However, the serum PAPP-A levels in the untreated patient group were found to be higher than those in the control group, but this difference was not statistically significant (p=0.086). The serum PAPP-A and IGFBP-4 levels are elevated in lung cancer. However, IGFBP-4 may have better potential than PAPP-A as a lung cancer biomarker.
胰岛素样生长因子结合蛋白4（IGFBP - 4）是胰岛素样生长因子（IGF）家族的成员之一，负责运输并调节IGF的活性。妊娠相关血浆蛋白A（PAPP - A）对IGFBP - 4具有蛋白水解活性，这两种蛋白都与包括肺癌在内的多种癌症有关。因此，我们旨在评估IGFBP - 4和PAPP - A作为肺癌潜在生物标志物的用途。本研究纳入了83名志愿者，其中包括60名肺癌患者和23名健康个体。肺癌患者根据其治疗状态、组织学亚组和疾病分期进行选择。采用酶联免疫吸附测定法评估血清中IGFBP - 4和PAPP - A的水平，而IGF - 1水平则使用化学发光免疫分析法进行测定。所有患者组的血清IGFBP - 4水平，无论治疗状态和组织学差异如何，均显著高于对照组（p<0.005）。然而，未治疗患者组的血清PAPP - A水平虽高于对照组，但差异无统计学意义（p = 0.086）。肺癌患者血清中PAPP - A和IGFBP - 4水平升高。然而，作为肺癌生物标志物，IGFBP - 4可能比PAPP - A具有更好的潜力。
